PUBLICATIONS

[Peer Reviewed Original Manuscripts]

[Reviews and Book Chapters]

 

Peer Reviewed Original Manuscripts:

  1. de Lecea L, Jones BE, Boutrel B, Borgland SL, Nishino S, Bubser M, DiLeone R (2006). Addiction and arousal: alternative roles of hypothalamic peptides. J Neurosci. Oct 11;26(41):10372-5. pubmed
  2. Satoh S, Matsumura H, Kanbayashi T, Yoshida Y, Urakami T, Nakajima T, Kimura N, Nishino S, Yoneda H (2006). Expression pattern of FOS in orexin neurons during sleep induced by an adenosine A2A receptor agonist. Behav Brain Res. 170(2):277-86. pubmed
  3. Fujiki N, Yoshida Y, Zhang S, Sakurai T, Yanagisawa M, Nishino S (2006). Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models. Peptides. 27(9):2326-2331. pubmed
  4. Arnulf I, Lin L. Zhang J, Russel IJ, Ripley B, Einen M, Nevsimalova S, Bassetti C. Bourgin P, Nishino S, Mignot E (2005) CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency?, Sleep, 29(8):1017-24. pubmed
  5. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, Naghdi N, Yanai K. (2005) Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain, 118:254-262. pubmed
  6. Dohi K, Nishino S, Yoshida Y, Nakamachi  T, Ohtaki H,  Shioda S, Aruga T. (2006) CSF orexin A levels and Orexin-1 receptor expressions in the rat hippocampus after cardiac pulmonary arrest, Neuropeptide, 40(4):245-250. pubmed
  7. Kita I, Yoshida Y, Nishino S. (2005) An activation of parvocellular oxytocinergic neurons in the hypothalamic paraventricular nucleus is associated with oxytocin-induced yawning and penile erection. Neuroscience Research, 54 (4): 269-275. pubmed
  8. Grady S, Nishino S, Czeisler C, Hepner D, Scammell TE. (2006) Diurnal Variation in CSF Orexin-A in Healthy Male Subjects,  Sleep, 29(3):295-297. pubmed
  9. Tachibana N, Taniike M, Okinaga T, Ripley B, Mignot E, Nishino S. (2005) Hypersomnolence and increased REM sleep with low CSF hypocretin level in a patient after removal of craniopharyngioma. Sleep Med, 6:567-569. pubmed
  10. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Hiroyuki Watanabe H, Kato M, Yanai K. (2005) Enhanced antinociception by intracerebroventricularly and  intrathecally-administered orexin A and B (hypocretin-1 and -2)   in mice. Peptides, 26 :767-777. pubmed
  11. Philipp U, Hamann H, Mecklenburg L,  Nishino S, Mignot E, Schmutz SM, Tosso Leeb T (2005). Polymorphisms within the canine MLPH gene are associated with dilute coat color in Doberman Pinschers. BMC genetics, 16; 6:34. pubmed
  12. Nevsimalova S, Vankova J, Stepanova I, Seemanova E, Mignot E, Nishino S. (2005) Hypocretin deficiency in Prader-Willi syndrome. Eur J Neurol. 12(1):70-2. pubmed
  13. Dohi K, Ripley B, Fujiki N, Nakamachi T, Ohtaki H, Shioda S, Aruga T, Nishino S. (2005) CSF hypocretin-1/orexin A concentrations in patients with subarachnoid hemorrhage (SAH), Peptides, 26:2339-2343. pubmed
  14. Desarnaud F, Murillo-Rodriguez E, Lin L, Xu M, Gerashchenko D, Shiromani SN, Nishino S, Mignot E, Shiromani PJ (2004), The diurnal rhythm of hypocretin in young and old F344 rats. Sleep. 7(5):851-6. pubmed
  15. Zhang S, Zeitzer JM, Yoshida Y, Wisor JP, Nishino S, Edgar DM, Mignot E. (2004) Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep. 15;27(4):619-27. pubmed
  16. Satoh S, Matsumura, H, Fujioka, A, Nakajima T, Kanbayashi T, Nishino N, Shigeyoshi Y, Yoneda (2004) FOS expression in orexin neurons following muscimol perfusion of preoptic area Neuroreport. 15:1127-1131. pubmed
  17. Yoshikawa S, Suzuki S, Kanbayashi T,  Nishino S, Tamai H (2004) Hypersomnia and low cerebrospinal fluid hypocretin levels in acute disseminated encephalomyelitis.Pediatr Neurol. Nov;31(5):367-70. pubmed
  18. Gledhill RF, Bartel PR, Nishino S, Yoshida Y, Scammell TE, MD (2004) Narcolepsy due to acute disseminated encephalomyelitis, Ann Neurol, 61:758-760. pubmed
  19. Arii J, Kanbayashi T, Tanabe Y, Sawaishi Y, Kimura S,  Watanabe A, Mishima K, Hishikawa Y, Shimizu T, Nishino S (2004) CSF hypocretin-1 (orexin-A) levels in pediatric narcolepsy and neurologic disorders. Neurology, 63:2440-2442. pubmed
  20. Desarnaud F, Murillo-Rodriguez E, Lin L, Rector T, Shiromani S, Lu J,Xu M, Dmitry Gerashchenko D, Nishino S, Mignot E, Shiromani P.J. (2004) Gene expression profiling in the posterior hypothalamus of young and old rats. Sleep, 27 (5):851-6. pubmed
  21. Okura M, Fujiki N, Kita I, Honda K, Mignot E, Nishino S (2004).  The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. Neurobiology of Disease, 16:274-82. pubmed
  22. Pedrazzoli M, Ling L, D'Almeida V, Forcina P, Nishino S, Tufik S, Mignot E (2004) Hypocretin levels in rat CSF after paradoxical (REM) sleep deprivation. Brain Resaerch, 995:1-6. pubmed
  23. Overeem S, Dalmau J, Bataller L, Nishino S, Mignot E, Verschuuren J, Lammers GJ (2004). Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology. Jan 13;62(1):138-40. pubmed
  24. Yoshida Y, Fujiki N, Maki RA, Schwarz D, Nishino S (2003) Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 346:182-186. pubmed
  25. Vankova J, Stepanova I, Jech R, Elleder M, Ling L, Mignot E, Nishino S, Nevsimalova S (2003) Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep, 26:427-430. pubmed
  26. Satoh S, Matsumura H, Nakajima T, Nakahama K, Kanbayashi T, Nishino S, Yoneda H, Shigeyoshi Y (2003) Inhibition of rostral basal forebrain neurons promotes wakefulness and induces FOS in orexin neurons. Eur J Neurosci, 17:1635-1645. pubmed
  27. Fujiki N, Ripley B, Yoshida Y, Mignot E, Nishino S (2003) Effects of IV and ICV hypocretin-1 (Orexin A) in hypocretin receptor-2 mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep, 15:26 (8) 935-939. pubmed
  28. Tonokura M, Fujita K, Morozumi, M,  Yoshida, Y, Kanbayashi, T, Nishino, S (2003). Case of a hypocretin/orexin-deficient narcoleptic Chihuahua. Vet Rec, 152(25):776-9. pubmed
  29. Fujiki. N, Morris L, Mignot, E, Nishino, S (2002). Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy. Psychiatry Clin Neurosci. Jun;56(3):275-6. pubmed
  30. Kanbayashi  T, Inoue Y, Chiba S, Aizawa R, Saito Y, Tsukamoto H, Fujii Y, Nishino S, Shimizu T (2002). CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res. 11(1):91-3. pubmed
  31. Kanbayashi  T, Yano T, Ishiguro H, Kawanishi K, Chiba S, Aizawa R, Sawaishi Y, Hirota K, Nishino S, Shimizu T (2002).  Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep. 25(3):337-9. pubmed
  32. Kanbayashi  T, Ishiguro H, Aizawa R, Saito Y, Ogawa Y, Abe M, Hirota K, Nishino S, Shimizu T (2002). Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barre syndrome. Psychiatry Clin Neurosci. 56(3):273-4. pubmed
  33. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, Mignot E, Shiromani PJ (2003).  Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol. Dec;184(2):1010-6. pubmed
  34. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, Mignot E  (2003).  Diurnal variation of CSF hypocretin-1 (orexin-A) levels in control and depressed subjects.  Biol Psychiatry 54 (2) :96-104. pubmed
  35. Bassetti C, Gugger M, Bischof M, Mathis J, Sturzenegger C, Werth E, Radanov B, Ripley B, Nishino S, Mignot E (2003).  The Narcoleptic borderland:  A multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (Orexin A).  Sleep Medicine,  4 (1):7-12. pubmed
  36. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ Vankova J,  Okun M, Rogers W, Brooks S, Mignot E (2002). Reply to letter by Schuld et al. Ann Neurol, 51:660-661. pubmed
  37. Nishino S, Mignot E (2002) Article reviewed: Plasma orexin-A is lower in patients with narcolepsy. Sleep Med 3:377-378. pubmed
  38. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S (2002).  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Archives of Neurology 59:1553-1562. pubmed
  39. Lin L, Wisor J, Shiba T, Taheri S, Yanai K, Wurts S, Lin X, Vitaterna M, Takahashi J, Loveberg TW, Koehl M, Uhl G, Nishino S, Mignot E (2002).  Measurement of hypocreto/orexin content in the mouse brain using an enzyme immunoassay: The effect of circadian time, age and genetic background. Peptides. 23(12):2203-11. pubmed
  40. Allen RP, Mignot E, Ripley B, Nishino S, Earley CJ (2002) Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 59:639-641. pubmed
  41. Voderholzer U, Riemann D, Gann H, Hornyak M, Juengling F, Schumacher M, Reincke M, von Herbay A, Nishino S, Mignot E, Berger M, Lieb K (2002).  Transient total sleep loss in a patient with cerebral Whipple's disease: A longitudinal study.  J Sleep Res, 11(4):321-9. pubmed
  42. Shiba T, Ozu M, Yoshida Y, Mignot E, Nishino S (2002).  Hypocretin stimulates [(35)S]GTPgammaS binding in Hcrtr 2-transfected cell  lines and in brain homogenate. Biochem Biophys Res Commun, 294(3): 615-20. pubmed
  43. Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ (2002).  Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness.  Neurology, 58: 498-499. pubmed
  44. Hong S-C, Leen-Kim L, Park S-A, Han J-H, Lee S-P, Lin L, Okun M, Nishino S, Mignot E (2002).  HLA and hypocretin studies in Korean patients with narcolepsy. Sleep, 25(4) 440-444. pubmed
  45. Nishino S, Ripley B, Mignot E, Benson KL, Zarcone VP.(2002).  CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res,110(1): 1-7. pubmed
  46. Banno K, Shiomi T, Sasanabe R, Hasegawa R, Otake K, Yamakawa H, Kobayashi T, Horiba K, Nishino S (2001) Narcolepsy and other non-SAS hypersomnia in sleep breathing disorders clinic. Psychiatry Clin Neurosci 55:203-204. pubmed
  47. Urakami T, Kuroda K, Kanbayahi T, Emura N, Mandai H, Matsumura H, Yoshida Y, Nishino S, Yoneda H (2003) Levels of hypocretin-1 (orexin A) in the cerebrospinal fluid of two young hypoersomniacs suspected of being narcoleptic,  Sleep and Biological Rhythms, 1 (2): 167-168. pubmed
  48. Fujiki N, Yoshida Y, Shiba T, Parnis S, Nishino S (2003) Vagus nerve stimulation modulates cataplexy in narcoleptic dogs, Sleep and Biological Rhythms, in press. pubmed
  49. Simon BK, Nishino S, Scammell TE (2003) Mistaken diagnosis of psychogenic  attacks. Movement Disorders, 19:838-840. pubmed
  50. Okura M, Fujiki N, Ripley B, Takahashi S, Amitai N, Mignot E, Nishino S (2001). Narcoleptic canines display periodic leg movements during sleep. Psychiatry & Clinical Neurosciences. 55(3):243-4. pubmed
  51. Arii J, Kanbayashi T, Tanabe Y, Ono J, Nishino S, Kohno Y (2001). A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology, 56(12):1775-6. pubmed
  52. Hartwig G, Harsh J, Ripley R, Nishino S, Mignot E (2001).  Low cerebrospinal fluid levels found in familial narcolepsy.Sleep Medicine 2 (5) 451-453. pubmed
  53. Ripley B,  Overeem S, Fujiki  N, Nevsimalova S,  Uchino M, Yesavage J, Di MonteD, Dohi K, Melberg A, Lammers GJ, Nishida Y, Roelandse FWC; Hungs M, E. Mignot E., Nishino S (2001).  CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.   Neurology, 57: 2253-2258. pubmed
  54. Nishino S, Fujiki N, Ripley B, Sakurai E, Kato M, Watanabe T, Mignot E, Yanai K (2001).  Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.  Neurosci Lett 313: 125-128. pubmed
  55. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, Mignot E, Nishino S  (2001).  Fluctuation of extracellular hypocretin-1 (orexin-A) levels in the rat in relation to the ligh/dark cycle and sleep/wake activities.  Eur J Neurosci, 14: 1075-1081. pubmed  
  56. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ Vankova J,  Okun M, Rogers W, Brooks S, Mignot E  (2001). Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy.   Ann Neurol, 50: 381-388. pubmed
  57. Scammell TE, Nishino S, Mignot E, Saper CB  (2001).  Narcolepsy and Low CSF Orexin (hypocretin) concentration following a Diencephalic Stroke. Neurology, 56: 1751-1753. pubmed
  58. Wisor JP, Nishino S, Sora I, Uhl  GH, Mignot E, Edgar DM  (2001).  Sleep Regulation and Response to Stimulants are Impaired in DAT Knockout Mice.  J Neurosci, 21(5): 1787-1794. pubmed
  59. Ripley B, Okura, M, Fujiki. N. Mignot E, Nishino S  (2001). Hypocretin levels in sporadic and familial cases of canine narcolepsy.   Neurobiol Dis, 8: 525-534. pubmed
  60. Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S  (2001). Changes in CSF Hypocretin-1 (Orexin A) Levels in Rats Across 24 Hours and in Response toFood Deprivation.  NeuroReport 12(5): 993-997. pubmed
  61. Melberg A, Ripley B, Lin L, Hetta J, Mignot E, Nishino S (2001). Hypocretin deficiency in familial symptomatic narcolepsy. Ann Neurol, 49: 136-137. pubmed
  62. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000): A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000 6(9):991-7. pubmed
  63. Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E (2000) Is narcolepsy REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neuroscience Research, 38 (4): 437-446. pubmed
  64. Nishino S, Ripley B, Overeem S, Lammers GL, Mignot E (2000) Hypocretin (orexin) transmission is defective in human narcolepsy. Lancet, 355: 39-40. pubmed
  65. Kanbayashi T, Honda K, Kodama T, Mignot E, and Nishino S (2000) Implication of Dopaminergic Mechanisms in the Wake Promoting Effects of Amphetamine: A Study of D- and L- Derivatives in Canine Narcolepsy. Neuroscience. 99(4):651-659. pubmed
  66. Okura M, Riehl J, Mignot E, Nishino S (2000) Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology, 23 (5) 528-538. pubmed
  67. Nishino S, Okura M, Mignot E (2000).  Narcolepsy: Genetic prediction and neuropharmacological mechanisms.  Sleep Med Rev, 4 (1):57-99. pubmed
  68. Riehl J, Honda H, Kwan M, Hong J, Mignot  E, Nishino, S (2000). Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy.  Neuropsychopharmacology, 23(1):34-45. pubmed
  69. Riehl J, Okura M, Mignot E, Nishino S (2000).  Inheritance of Von Willerbrand's disease in a colony of Doberman pinschers.  Am J Vet Res, 61 (2): 115-120. pubmed
  70. Nishino S, Mignot E (1999) Drug treatment of patients with insomnia and excessive daytime sleepiness: Pharmacokinetics considerations. Clin Pharmacokinetics, 37(10): 305-330. pubmed
  71. Honda K, Riehl J, Mignot  E, Nishino S (1999) Dopamine D3 agonists into the substantia nigra aggravates cataplexy but does not modify sleep.  NeuroReport 17(10): 3717-3724. pubmed
  72. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong P, Nishino S, Mignot E (1999).  The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.  Cell 98(3): 365-376. pubmed
  73. Nishino S, Honda K, Riehl J, Okura M, Mignot E (1998).  Neuronal activity in the cholinoceptive basal forebrain of freely-moving narcoleptic Dobermans.  NeuroReport, 9: 3653-3661. pubmed
  74. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E (1998).  Development of cataplexy in genetically narcoleptic Dobermans.   Exp Neurology, 152: 292-302. pubmed
  75. Nishino S, Mao J, Sampathkuraran R, Shelton J, Mignot E (1998).  Increased dopaminergic transmission mediates alerting effects of CNS stimulants.  Sleep Res Online, 1: 49-61. pubmed
  76. Cederberg R, Nishino S, Dement WC, Mignot E  (1998).  The Stanford narcoleptic canine colony: twenty years of breeding history.  Vet Res, 142: 31-36. pubmed
  77. Nishino S, Mignot E, Benson KL, Zarcone ZP  (1998).  Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture.  Psychiatry Res, 78: 141-150. pubmed
  78. Nishino S, Mignot E (1998).  Neurobiology of narcolepsy.  The Neuroscientist, 4: 133-143. pubmed
  79. Nishino S and Mignot E  (1997).  Pharmacological aspects of human and canine narcolepsy.  Prog Neurobiol, 52(1): 27-78. pubmed
  80. Nishino S, Tafti M, Sampathkumaran R, Dement WC, Mignot E  (1997).  Circadian distribution of rest/activity in narcoleptic and control dogs: assessment with ambulatory activity monitoring.  J Sleep Res, 6: 120-127. pubmed
  81. Reid M, Nishino S, Tafti M, Siegel JM, Dement WC, Mignot E (1997).  Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines.  Exp Neurology, 151: 89-104. pubmed
  82. Nishino S, Arrigoni J, Shelton J, Kanbayashi T, Dement WC, Mignot E  (1997). Effects of thyrotropin releasing hormone (TRH) and its analogs on daytime sleepiness and cataplexy in canine narcolepsy.   J Neurosci, 17: 6401-6408. pubmed
  83. Honda K, Riehl J, InoueL S, Mingnot E, Nishino S (1997).  Central administration of vitamin B12 aggravates cataplexy in canine narcolepsy.  NeuroReport, 8: 3861-3865. pubmed
  84. Kanbayashi T, Nishino S, Tafti M, Hishikawa Y, Dement WC, Mignot E  (1996).  Thalidomide,a  hypnotic with immune  modulating properties  in canine narcolepsy.  NeuroReport, 7(12): 1881-1886. pubmed
  85. Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E  (1996).  Major histocompatibility  class II molecules  in the CNS: increased microglial expression at the onset of narcolepsy  in a canine  model.   J Neurosci, 16(15): 4588-4595. pubmed
  86. Tafti M, Nishino S, Liao W, Dement WC, Mignot E  (1997).  Mesopontine organization of cholinergic and catecholaminergic cell group in the normal and narcoleptic dogs.  J Comp Neurol, 379: 185-197. pubmed
  87. Reid MS, Tafti M, Nishino S, Sampathkumaran R, Siegel J, Mignot E  (1996).  Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine.  Brain Res, 733(1): 83-100. pubmed
  88. Kanbayashi T, Nishino S, Tafti M, Hishikawa T, Dement WC, Mignot E  (1996).  Thalidomide, dramatically  aggravates canine cataplexy.    Sleep (Letter to Editor), 19(2): 116. pubmed
  89. Shelton J, Nishino S, Vaught J, Dement WC, Mignot E  (1995).  Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of  narcoleptic dogs.  Sleep, 18: 817-826. pubmed
  90. Nishino S, Tafti M, Reid M, Shelton J, Siegel JM, Dement WC, Mignot E  (1995).  Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication of the pathophysiology of narcolepsy.  J Neurosci, 15: 4806-4814. pubmed
  91. Nishino S, Shelton J, Renaud A, Dement WC, Mignot E  (1995).  Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy.  J Pharmacol Exp Ther, 272: 1170-1175. pubmed
  92. Nishino S, Reid MS, Dement WC, Mignot E  (1994). Neuropharmacology and Neurochemistry of canine narcolepsy.  Sleep, 17: S84-S93. pubmed
  93. Mignot E, Nishino S, Guilleminault C, Dement WC  (1994).  Modafinil binds to the dopamine uptake carrier site with low affinity.  Sleep, 17: 436-437. pubmed
  94. Reid MS, Tafti M, Nishino S, Siegel JM, Dement WC, Mignot E  (1994).  Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors.  Sleep, 17: 424-435. pubmed
  95. Reid MS, Tafti M, Geary J, Nishino S, Siegel JM, Dement WC, Mignot E  (1993).  Cholinergic mechanisms in canine narcolepsy: I. Modulation of cataplexy via local drug administration into pontine reticular formation.  Neuroscience,  59: 511-522. pubmed
  96. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E  (1993).  Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds.  Sleep, 16: 706-712. pubmed
  97. Mignot E, Renaud A. Nishino S, Arrigoni J, Guilleminault C, Dement WC  (1993).  Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers.  Psychopharmacology, 113: 76-82. pubmed
  98. Mignot E, Nishino S, Hunt Sharp L, Arrigoni J, Siegel JM, Reid MS, Edgar DM, Ciaranello RD, Dement WC  (1993).  Heterozygocity at the canac-1 locus can confer susceptibility  for narcolepsy:  induction of cataplexy  in heterozygous asymptomatic  dogs after administration of a combination of drugs after administration of drugs acting on monoaminergic  and cholinergic  systems.  J Neurosci, 13: 1057-1064. pubmed
  99. Nishino S, Fruhstorfer B, Arrigoni J, Guilleminault C. Dement WC, Mignot E  (1993).  Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy.   J Pharmacol Exp Ther, 264: 1079-1084. pubmed
  100. Nishino S, Arrigoni J, Hunt Sharp L, Shelton JD, Dement WC, C, Mignot E  (1992).  Serum prolactin response to a D2 antagonists in narcoleptic and control canines.  Sleep, 15: 474-475. pubmed
  101. Renaud A, Nishino S, Dement WC, Guilleminault C, Mignot E  (1991).  Effect of SDZ NVI-085, a putative subtype selective alpha-1 agonist on canine cataplexy.   Eur J Pharmacol,  205: 11-16. pubmed
  102. Nishino S, Arrigoni J, Mignot E, Valtier D, Miller J, Guilleminault C, Dement WC  (1991).  Dopamine D-2 mechanisms in canine narcolepsy.  J Neurosci, 11: 2666-2671. pubmed
  103. Nishino S, Mignot E, Kuroda K, Sakai T, Dement WC.  (1990): Involvement of central noradrenergic and cholinergic mechanisms in control of cataplexy in canine narcolepsy (in Japanese). Shinkei Kenkyu no Shinpo (Advances in Neurological Sciences) 34: 461-473. pubmed
  104. Valtier D, Nishino S, Guilleminault C, Mignot E, Dement WC  (1990).  Platelet alpha-2 adrenoceptors in human and canine narcolepsy.  Biol Psychiatry, 29: 376-382. pubmed
  105. Nishino S, Mignot E, Kilduff TS, Sakai T, Hayaishi O, Dement WC  (1990).  Prostaglandin E2 levels in cerebrospinal fluid of normal and narcoleptic dogs.  Biol Psychiatry, 28: 904-910. pubmed
  106. Nishino S, Haak L, Shepherd H, Guilleminault C, Sakai T, Dement WC, Mignot E  (1990).  Effects of central alpha-2 adrenergic compounds on canine narcolepsy, a disorder of rapid eye movement sleep.  J Pharmacol Exp Ther, 253: 1145-1152. pubmed
  107. Mignot E, Guilleminault C, Bowersox S, Fruhstorfer B, Nishino S, Maddaluno J, Ciaranello R, Dement WC  (1989).  Central alpha-1 adrenoceptor subtypes in narcolepsy-cataplexy: A disorder of REM sleep.  Brain Res, 490: 186-191. pubmed
  108. Fruhstorfer B, Mignot E, Bowersox S, Nishino S, Dement WC, Guilleminault C  (1989).  Canine narcolepsy is associated with an elevated number of alpha-2 receptors in the locus coeruleus.  Brain Res, 500: 209-214. pubmed
  109. Nishino S, Mignot E, Fruhstorfer B, Dement WC, Hayaishi O  (1989).  Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy.  Proc Natl Acad Sci (USA), 86: 2483-2487. pubmed

 

 


Seiji Nishino, M.D., Ph.D. and Stanford University, 2007
All Rights Reserved.